The study elegantly demonstrated that XBP1-deficient T cells enriched effector function in mouse models of ovarian cancer, providing evidence for the IRE1α axis as an immunotherapeutic target in cancer (Song et al., 2018). Here, XBP1 is linked to ovarian cancer.